CTRI/2021/06/034015招募中3 期
A Multi-Centre, Prospective, Open Label, Parallel, Randomized, Clinical Trial toAssess the Efficacy And Safety Of Molnupiravir 800 Mg Capsules And Standard of Care (SoC) Compared To Standard of Care (SoC) Only In Mild Patients With Polymerase Chain Reaction (PCR)Confirmed COVID-19.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements.
- •Male or female patients between 18 and 60 years of age (both inclusive).
- •Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected ââ?°Â¤5 days prior to randomization)
- •Patients with mild COVID-19 (non-hospitalized) and have following symptoms and signs within 3 to 5 days prior to randomization.
- •Patients having mild COVID-19 with a score of 2 or 3 on the 10-point ordinal scale of clinical status
- •Patients who are able to consume oral medications.
- •Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention:
- •Females who are not pregnant or breastfeeding
排除标准
- •Known hypersensitivity or contraindications to any of the components of the study interventions or to any other similar class of drugs as determined by the investigator.
- •Uncontrolled comorbid medical conditions.
- •Patient is currently hospitalized or is expected to need hospitalization for COVID-19 within 48 hours of randomization
- •Patient is on dialysis or has reduced estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 by the Modification of Diet in Renal Disease (MDRD) equation.
- •If patient has any of the following conditions: human immunodeficiency virus (HIV); chemotherapy required within 6 weeks before randomization; a neutrophilic granulocyte absolute count <500/mm3; autologous or allogeneic hematopoietic stem cell transplant recipient.
- •If patient has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3X upper limit of normal at screening.
- •If patient has a platelet count <100,000/Ã?¼L or received a platelet transfusion in the 5 days prior to randomization.
- •Patient has a history of acute pancreatitis within 3 months prior to randomization or a history of chronic pancreatitis.
- •Patient is currently receiving or anticipated to require any prohibited medications/ therapies (e.g. Favipiravir, oseltamivir or any other anti-viral treatments) during study participation as per investigatorââ?¬•s discretion.
- •A baseline heart rate of < 60 beats per minute at rest
- •If patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, participants who are expected to require mechanical ventilation within 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents.
研究者
相似试验
已完成
4 期
A clinical study to evaluate the safety and efficacy of Heparin Injection for prophylaxis and treatment as anticoagulant and thrombolytic in Deep Vein Thrombosis and Pulmonary EmbolismCTRI/2013/02/003359irma Limited Nirlife Healthcare
招募中
4 期
A Post Marketing Surveillance study of BCG vaccine in Indian populatioCTRI/2009/091/000669Green Signal BioPharma Pvt. Ltd., Chennai, India1,000
尚未招募
4 期
se Of Amlapitta Mishran suspension in treatment of Amlapitta (Hyperacidity)CTRI/2022/05/042670Shree Dhootapapeshwar Limited
进行中（未招募）
不适用
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children.Severe Respiratory Syncytial Virus Infection (RSV)MedDRA version: 17.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-004527-42-Outside-EU/EEAAbbott Laboratories LLC100
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 20.0 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-SKAB Science80